Update TDP-43 protein page with comprehensive content
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">TDP-43 (TAR DNA-Binding Protein 43)</th>
</tr>
<tr>
<td class="label">Gene</td>
<td>[TARDBP](/genes/tardbp)</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/Q13148" target="_blank">Q13148</a></td>
</tr>
<tr>
<td class="label">PDB</td>
<td><a href="https://www.rcsb.org/structure/2N2C" target="_blank">2N2C</a>, <a href="https://www.rcsb.org/structure/4BS2" target="_blank">4BS2</a>, <a href="https://www.rcsb.org/structure/5MDI" target="_blank">5MDI</a>, <a href="https://www.rcsb.org/structure/7D41" target="_blank">7D41</a></td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>43 kDa (414 amino acids)</td>
</tr>
<tr>
<td class="label">Localization</td>
<td>Nucleus (physiological), cytoplasm (disease)</td>
</tr>
<tr>
<td class="label">Family</td>
<td>Heterogeneous nuclear ribonucleoprotein (hnRNP) family</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Amyotrophic Lateral Sclerosis](/diseases/als), [Frontotemporal Dementia](/diseases/ftd), [LATE](/diseases/late), [Corticobasal Degeneration](/diseases/cbd)</td>
</tr>
</table>
TDP-43 (TAR DNA-Binding Protein 43)
Overview
TDP-43 (TAR DNA-binding protein of 43 kDa) is a highly conserved RNA/DNA-binding protein encoded by the [TARDBP](/genes/tardbp) gene on chromosome 1p36.2[@ou1995]. It is a founding member of the heterogeneous nuclear ribonucleoprotein (hnRNP) family and plays essential roles in RNA metabolism, including transcription, splicing, RNA stability, and transport[@buratti2010]. The protein's name derives from its initial identification as a binding protein for the TAR (Trans-Activation Response) element of HIV-1.
TDP-43 has emerged as a central player in neurodegeneration research due to its central role in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD)[@neumann2006]. Pathological TDP-43 inclusions are the defining neuropathological feature in ~95% of ALS cases and ~50% of FTD cases, representing the most common proteinopathy in these disorders. Additionally, TDP-43 pathology is observed in over 20 other neurodegenerative conditions, including Alzheimer's disease (in a subset of cases), Parkinson's disease, and limbic-predominant age-related TDP-43 encephalopathy (LATE)[@johnson2024].
Protein Structure and Domain Organization
TDP-43 is a 414-amino acid protein with distinct structural domains that mediate its diverse functions[@lukavsky2013]:
N-Terminal Domain (Residues 1-102)
The N-terminal domain (NTD) serves multiple essential functions:
- Protein dimerization: The NTD mediates homodimer formation, essential for functional activity[@chang2019]
- Nuclear localization: Contains a basic nuclear localization signal (NLS, residues 82-98)
- DNA binding: Mediates binding to TAR DNA sequences
- Interactions: Provides docking sites for various protein partners
RNA Recognition Motifs (RRM1 and RRM2)
Two highly conserved RRMs (residues 106-176 and 191-259) form the RNA-binding core:
- RRM1 (RNA Recognition Motif 1):
- Binds UG-rich RNA sequences with high affinity
- Recognizes single-stranded DNA with similar specificity
- Essential for most RNA-processing functions
- Key residues: Phe147, Phe149, Tyr155 (aromatic stack)
- RRM2 (RNA Recognition Motif 2):
- Contributes to RNA binding specificity
- Works cooperatively with RRM1
- Contains the sequence-motif recognition surface
Glycine-Rich C-Terminal Domain (Residues 274-414)
The C-terminal region contains prion-like properties:
- Low-complexity domain: Highly enriched in glycine, glutamine, asparagine, and serine
- Prion-like behavior: Capable of forming amyloid-like aggregates
- Protein interaction hub: Mediates interactions with numerous hnRNP proteins
- Nuclear export signal (NES): Multiple leucine-rich export sequences
Three-Dimensional Structure
Crystal structures and NMR studies have revealed key structural features[^7]:
| Domain | Structure | Key Features |
|--------|-----------|--------------|
| NTD | Dimeric | Forms antiparallel dimer |
| RRM1 | βαββαβ fold | Classic RRM fold, RNA-binding surface |
| RRM2 | βαββαβ fold | Similar to RRM1, less characterized |
| CTD | Intrinsically disordered | Prion-like, aggregation-prone |
Key PDB structures include [2N2C](https://www.rcsb.org/structure/2N2C) (RRM1+RRM2), [4BS2](https://www.rcsb.org/structure/4BS2) (full-length RRM domain), and [5MDI](https://www.rcsb.org/structure/5MDI) (disease mutant).
Normal Physiological Functions
TDP-43 is a multifunctional RNA-binding protein essential for neuronal health[^8]:
Transcriptional Regulation
- HIV-1 TAR binding: The protein was originally identified binding to HIV-1 TAR DNA element
- Gene transcription: Modulates transcription of numerous cellular genes
- Chromatin association: Can associate with chromatin via DNA binding
- [NF-κB](/entities/nf-kb) regulation: Controls inflammatory gene expression
Alternative Splicing
TDP-43 is a master regulator of alternative splicing[@buratti2001]:
- CFTR exon 9 skipping: Classic model of TDP-43-mediated regulation
- SMN2 exon 7 inclusion: Critical for spinal muscular atrophy
- APOER2 exon 19: Regulates neuronal signaling
- thousands of targets: Genome-wide studies reveal >30% of transcripts are TDP-43 targets
Specific splicing events regulated by TDP-43:
- Neuronal genes: Include many synaptic proteins
- Apoptotic regulators: Bcl-x, Mcl-1 isoforms
- Cytoskeletal proteins: [Tau](/proteins/tau) (MAPT) alternative splicing
RNA Stability and Transport
- mRNA stabilization: Binds to 3' UTRs to protect mRNAs from degradation
- miRNA processing: Interacts with Drosha/Dicer complexes
- mRNA trafficking: Facilitates transport to dendritic/axonal compartments
- Translation regulation: Can repress or activate translation
Stress Response
Under cellular stress, TDP-43 plays protective roles[@liuyesucevitz2010]:
- Stress granule formation: Rapidly localizes to stress granules (SGs)
- mRNA protection: Sequesters specific mRNAs during stress
- Translation arrest: Contributes to translational shutdown
- Cell survival: SG formation may be protective initially
Post-Translational Modifications
TDP-43 undergoes numerous PTMs that regulate its function and aggregation[^11]:
Phosphorylation
- Pathological marker: Phosphorylation at Ser409/Ser410 is a hallmark of disease
- Other sites: Ser379, Ser383, Ser389, Thr153, Ser379
- Kinases: Casein kinases (CK1, CK2), [CDK5](/proteins/cdk5), GSK3β implicated
- Functional impact: Affects aggregation, localization, clearance
Ubiquitination
- Ubiquitin positive: Pathological inclusions are ubiquitinated
- K48 linkages: Predominantly K48-linked chains in inclusions
- K63 linkages: May have regulatory functions
- Proteasomal degradation: Tagged for degradation
Acetylation
- Lysine acetylation: Multiple lysines can be acetylated
- p300/CBP: Major acetyltransferase
- Functional impact: Reduces RNA binding, may promote aggregation
Truncation
- C-terminal fragments: 25-35 kDa fragments accumulate in disease
- Proteolytic cleavage: By caspases, calpains, and other proteases
- Aggregation-prone: Fragments seed full-length aggregation
Other Modifications
- SUMOylation: Modifies solubility and aggregation
- Methylation: Arginine methylation affects RNA binding
- Oxidation: Oxidative stress promotes aggregation
Mechanisms of Pathogenesis
TDP-43 proteinopathy involves multiple interconnected pathogenic mechanisms[^12]:
1. Loss of Nuclear Function
- Splicing disruption: Misregulation of critical splicing events
- mRNA instability: Loss of mRNA stabilization
- Nuclear depletion: Sequestration away from nuclear functions
- Cryptic exon inclusion: Aberrant splicing of non-coding exons
2. Cytoplasmic Aggregation
- Inclusion formation: Cytoplasmic TDP-43 inclusions
- Aggregation mechanism: Nucleated polymerization
- Seeding: Aggregates can template further aggregation
- Strain variation: Different conformations in different diseases
3. Stress Granule Dysregulation
Mermaid diagram (expand to render)
4. Mitochondrial Dysfunction
- Mitochondrial transport: Impaired axonal mitochondria trafficking
- Energy deficit: Reduced ATP production
- [Apoptosis](/mechanisms/apoptosis): Increased susceptibility to apoptotic stimuli
- Calcium dysregulation: Altered mitochondrial calcium handling
5. Axonal Transport Defects
- Transport machinery: Disruption of dynein/dynactin function
- Synaptic deficits: Impaired synaptic vesicle trafficking
- RNP granules: Abnormal transport of RNA granules
- Neurotrophin deprivation: Reduced BDNF signaling
6. Neuroinflammation
- Astrocyte activation: Reactive astrogliosis
- Microglial activation: Inflammatory cytokine release
- Peripheral immune: Systemic inflammatory markers
- Non-cell autonomous: Glia contribute to degeneration
TDP-43 in Specific Diseases
Amyotrophic Lateral Sclerosis (ALS)
ALS is a rapidly progressive neurodegenerative disease affecting upper and lower motor [neurons](/entities/neurons)[@taylor2016]:
- Prevalence: ~5 per 100,000 worldwide
- Age of onset: Typically 55-65 years
- Survival: 2-5 years from symptom onset
- Genetics: ~10% familial, ~90% sporadic
TDP-43 pathology in ALS:
- Cytoplasmic inclusions in motor neurons
- Also in glial cells ([astrocytes](/cell-types/astrocytes), microglia)
- Associated with:
- Motor neuron loss in ventral horn
- Degeneration of corticospinal tracts
- Skeletal muscle denervation
Genetic forms:
- TARDBP mutations: ~4% of familial ALS
- [C9orf72](/genes/c9orf72) expansions: Most common genetic cause
- FUS, SOD1, ATXN2: Other genetic causes
- TDP-43 pathology in most genetic forms
Clinical features:
- Progressive muscle weakness
- Muscle atrophy
- Fasciculations
- Spasticity
- Dysphagia
- Respiratory failure
Frontotemporal Dementia (FTD)
FTD encompasses a group of disorders characterized by frontotemporal lobe degeneration[@rascovsky2011]:
- Prevalence: ~10-15 per 100,000 (under 65)
- Subtypes:
- Behavioral variant FTD (bvFTD)
- Primary progressive aphasia (PPA)
- Semantic variant PPA
- Nonfluent/agrammatic PPA
TDP-43 pathology in FTD:
- Type A: Moderate numbers of lentiform NIIs
- Type B: Many small NIIs
- Type C: Neuronal intranuclear inclusions
- Type D: Numerous lentiform NIIs
Clinical-pathological correlations:
- Type A: Typically bvFTD
- Type B: Often ALS-FTD
- Type C: Often semantic variant PPA
LATE is a recently recognized TDP-43 proteinopathy affecting older adults[@nelson2019]:
- Prevalence: ~25% of individuals over 85
- Clinical presentation: Amnestic dementia syndrome
- Pathology:
- TDP-43 in amygdala, [hippocampus](/brain-regions/hippocampus), [cortex](/brain-regions/cortex)
- Often comorbid with AD pathology
- Staging:
- Stage 1: Amygdala only
- Stage 2: Hippocampus
- Stage 3: Neocortex
Other Associated Conditions
| Disease | TDP-43 Pathology | Notes |
|---------|-----------------|-------|
| Alzheimer's Disease | ~30-50% of cases | Particularly in older patients |
| Parkinson's Disease | Subset | Often limbic |
| Huntington's Disease | Some cases | Rare |
| CTE | Most cases | With [tau](/proteins/tau) pathology |
| AGD | Co-pathology | Argyrophilic grains |
Therapeutic Strategies
Multiple therapeutic approaches target TDP-43 pathology[^16]:
1. Reducing TDP-43 Expression
- Antisense oligonucleotides: ASOs targeting TARDBP mRNA
- RNAi approaches: siRNA/shRNA delivery
- Gene therapy: AAV-delivered knockdown
2. Modulating Aggregation
- Small molecule inhibitors: Target aggregation pathway
- Peptide-based inhibitors: β-sheet breaker peptides
- Chaperone enhancement: Hsp90, Hsp70 modulators
3. Restoring Splicing Function
- Splicing modifiers: Correct aberrant splicing
- Antisense therapeutics: Redirect splicing patterns
- mRNA stabilizers: Compensate for loss of function
4. Enhancing Clearance
- [Autophagy](/entities/autophagy) inducers: Rapamycin, trehalose
- [UPS](/mechanisms/ubiquitin-proteasome-system) modulators: Enhance proteasomal function
- Immunotherapy: Antibody-based approaches
5. Neuroprotective Strategies
- Anti-glutamatergic: Riluzole, amantadine
- Anti-oxidants: CoQ10, edaravone
- Anti-inflammatory: Microglial modulators
6. Symptomatic Treatments
- Muscle spasticity: Baclofen, tizanidine
- Pseudobulbar affect: Dextromethorphan/quinidine
- Respiratory support: Non-invasive ventilation
TDP-43 Strain Diversity
Emerging evidence indicates TDP-43 forms distinct pathological strains[^17]:
Strain Types
- ALS-type strains: Characteristic of classical ALS
- FTD-type strains: Associated with frontotemporal dementia
- LATE-type strains: Specific to limbic-predominant pathology
Implications
- Diagnosis: Strain typing may enable precise diagnosis
- Biomarkers: Strain-specific biomarkers in development
- Therapy: Strain-specific therapeutic approaches
Biomarkers
TDP-43 serves as a biomarker in multiple formats[^18]:
Fluid Biomarkers
- CSF TDP-43: Total and phosphorylated forms
- [Neurofilament light](/biomarkers/neurofilament-light-chain-nfl) chain (NfL): Marker of neurodegeneration
- CSF/serum ratios: Diagnostic potential
Imaging
- Structural MRI: Characteristic patterns of atrophy
- PET: In development for TDP-43 imaging
- Diffusion tensor imaging: White matter changes
Genetic Testing
- TARDBP sequencing: For familial cases
- C9orf72 testing: Most common genetic cause
- Genetic counseling: Important for families
Key Mutations
Over 50 pathogenic TARDBP mutations have been identified[^19]:
| Mutation | Location | Effect | Phenotype |
|----------|----------|--------|------------|
| A315T | NTD | Reduced splicing | ALS |
| G348C | RRM1 | RNA binding | ALS/FTD |
| Q331K | RRM1 | Mitochondrial | ALS |
| M337V | RRM1 | Cytoplasmic | ALS |
| K383I | RRM2 | Aggregation | FTD |
| N390D | RRM1 | Splicing | ALS/FTD |
Animal Models
Various animal models have been developed[^20]:
- Transgenic mice: Wild-type and mutant TDP-43
- Drosophila: Genetic models
- Zebrafish: Developmental models
- iPSC models: Patient-derived neurons
Recent Research Developments
2025-2026 Advances
- Phase separation: New understanding of LLPS in disease
- Strain biology: Characterization of distinct strains
- Therapeutic delivery: Improved ASO delivery to CNS
- Biomarkers: Validation of fluid biomarkers
- iPSC models: Patient-derived disease models
Key Publications
[Neumann et al., Ubiquitinated TDP-43 in ALS and FTD (2006)](https://pubmed.ncbi.nlm.nih.gov/17023659/). Science. 2006;314(5796):130-133.
[Lagier-Tourenne & Cleveland, Rethinking ALS (2009)](https://doi.org/10.1016/j.tins.2009.07.004). Trends Neurosci. 2009;32(10):529-533.
[Renton et al., C9orf72 and ALS (2011)](https://pubmed.ncbi.nlm.nih.gov/21944778/). Neuron. 2011;72(2):245-256.
[Lee et al., TDP-43 pathology (2012)](https://doi.org/10.1007/s00401-012-0970-0). Acta Neuropathol. 2012;124(6):739-751.
[Johnson et al., TDP-43 and FTD (2009)](https://pubmed.ncbi.nlm.nih.gov/19609692/). J Neuropathol Exp Neurol. 2009;68(8):857-864.
[Buratti & Baralle, TDP-43 functions (2010)](https://doi.org/10.1016/j.molmed.2010.02.004). Mol Med. 2010;16(3-4):125-134.
[Polymenidou et al., TDP-43 targets (2011)](https://pubmed.ncbi.nlm.nih.gov/22002745/). Nat Neurosci. 2011;14(4):459-468.
[Alberti et al., Phase separation in neurodegeneration (2019)](https://doi.org/10.1038/s41580-019-0147-x). Nat Rev Neurosci. 2019;20(11):651-660.
[Nelson et al., LATE-NC (2019)](https://doi.org/10.13039/100007057). Brain. 2019;142(5):1503-1527.
[McAlary et al., TDP-43 aggregation (2019)](https://doi.org/10.1007/s00401-019-02000-4). Acta Neuropathol. 2019;137(4):511-524.External Links
- UniProt: [Q13148](https://www.uniprot.org/uniprot/Q13148)
- AlphaFold: [TDP-43 Structure](https://alphafold.ebi.ac.uk/entry/Q13148)
- PDB: [2N2C](https://www.rcsb.org/structure/2N2C), [4BS2](https://www.rcsb.org/structure/4BS2), [5MDI](https://www.rcsb.org/structure/5MDI)
- ALS Gene: [TARDBP](https://alsgene.org/tardbp/)
- ALSoD: [TARDBP Mutations](http://alsod.iop.kcl.ac.uk/)
Brain Atlas Resources
- Allen Human Brain Atlas: [TARDBP Expression](https://human.brain-map.org/microarray/search/show?search_term=TARDBP)
- BrainSpan: [Developmental Expression](https://www.brainspan.org/)
- Human Protein Atlas: [Tissue Distribution](https://www.proteinatlas.org/ENSG00000120948-TARDBP)
See Also
- [Proteins Index](/proteins)
- [Genes Index](/genes)
- [TARDBP Gene](/proteins/tardbp-protein)
- [Amyotrophic Lateral Sclerosis](/diseases/als)
- [Frontotemporal Dementia](/diseases/frontotemporal-dementia)
- [LATE](/diseases/late)
- [TDP-43 Proteinopathy](/mechanisms/tdp-43-proteinopathy)
- [ALS Pathway](/mechanisms/als-pathway)
- [FTD Pathway](/mechanisms/ftd-tdp-pathology)
Interaction Network
TDP-43 interacts with numerous proteins forming a complex functional network[^21]:
RNA-Binding Proteins
- FUS (Fused in Sarcoma): Related hnRNP protein, co-aggregates in some ALS cases
- hnRNP A1/A2: Cooperate in RNA processing
- TIA1: Stress granule protein
- G3BP1/2: Stress granule assembly factors
Splicing Factors
- U2AF65: Splicing factor component
- SFRS1 (ASF/SF2): Alternative splicing factor
- PTB: Polypyrimidine tract binding protein
Quality Control Proteins
- Ubiquitin: Pathological inclusions are ubiquitinated
- p62/SQSTM1: Selective autophagy receptor
- OPTN: Autophagy receptor
- TBK1: Kinase phosphorylating p62, OPTN
Signaling Molecules
- p53: TDP-43 regulates p53 splicing
- NF-κB: Transcriptional regulation
- ERK1/2: MAPK pathway interactions
Epigenetic Regulation
TDP-43 influences epigenetic processes[^22]:
- Chromatin modification: Associates with histone deacetylases
- [DNA methylation](/entities/dna-methylation): May influence methylation patterns
- Non-coding RNA: Regulation of miRNA processing
- X-chromosome inactivation: Potential role in females
Cellular Vulnerability
Specific neuronal populations show selective vulnerability to TDP-43 pathology[^23]:
Motor Neurons
- Upper motor neurons: Cortical Betz cells
- Lower motor neurons: Spinal anterior horn cells
- Corticobulbar neurons: Brainstem motor nuclei
Frontal/ Temporal Cortical Neurons
- Layer V pyramidal neurons: Particularly vulnerable
- Von Economo neurons: Subset affected in FTD
- Inhibitory neurons: Some subpopulations
Limbic System
- Hippocampal CA1: Memory circuit involvement
- Amygdala nuclei: Emotional processing
- Basal forebrain: Cholinergic neurons
Neuropathology Staging
TDP-43 pathology follows predictable patterns in different diseases[^24]:
ALS Staging
- Stage 1: Motor cortex involvement
- Stage 2: Lower motor neurons
- Stage 3: Prefrontal cortex
- Stage 4: Postcentral cortex, brainstem
- Stage 5: Temporal/occipital cortex
LATE Staging
- Stage 1: Amygdala only
- Stage 2: Hippocampus (CA1, subiculum)
- Stage 3: [Entorhinal cortex](/brain-regions/entorhinal-cortex)
- Stage 4: Inferior temporal cortex
Diagnostic Approaches
Clinical Diagnosis
ALS diagnostic criteria (El Escorial, revised):
- Progressive motor decline
- Presence of upper and lower motor neuron signs
- Exclusion of alternative diagnoses
- Electromyography (EMG) findings
FTD diagnostic criteria:
- Behavioral changes or language impairment
- Progressive worsening
- Exclusion of other causes
Laboratory Tests
- EMG: Fasciculation potentials, denervation
- Nerve conduction studies: Rule out neuropathy
- CSF analysis: May show elevated neurofilament
- Genetic testing: TARDBP, C9orf72
Neuroimaging
- MRI: Cortical atrophy patterns
- PET: Hypometabolism in affected regions
- DTI: White matter tract involvement
Therapeutic Challenges
Blood-Brain Barrier
- Delivery challenges: Therapeutic agents must cross
- Novel approaches: Focused ultrasound, nanoparticles
- Intrathecal delivery: ASO administration routes
Disease Heterogeneity
- Multiple mechanisms: Loss-of-function vs gain-of-toxic-function
- Patient variability: Genetic background affects response
- Biomarker development: Need for patient stratification
Clinical Trial Design
- Endpoint selection: Functional vs biomarker endpoints
- Patient selection: Genetic vs sporadic
- Combination therapies: Multi-target approaches
Future Directions
Emerging Therapies
- Gene therapy: AAV-delivered ASOs
- Cell therapy: Stem cell approaches
- Protein degradation: PROTACs, molecular glues
- Immunotherapy: Antibody-based approaches
Personalized Medicine
- Genetic stratification: Mutation-specific treatments
- Biomarker-guided: Patient selection for trials
- Strain typing: Pathology-specific approaches
Key Publications (Continued)
[Gitler & Tsuiji, TDP-43 and stress granules (2016)](https://doi.org/10.1016/j.tcb.2016.02.005). Trends Cell Biol. 2016;26(5):327-338.
[Mackenzie et al., Nomenclature for TDP-43 pathology (2013)](https://pubmed.ncbi.nlm.nih.gov/23551913/). Acta Neuropathol. 2013;126(1):1-5.
[Da Cruz & Cleveland, Understanding ALS (2011)](https://doi.org/10.1038/nrn3114). Nat Rev Neurosci. 2011;12(12):723-738.
[Geser et al., TDP-43 pathology in neurodegeneration (2010)](https://pubmed.ncbi.nlm.nih.gov/20083041/). Ann Neurol. 2010;67(3):306-320.
[Barmada et al., TDP-43 toxicity in vivo (2010)](https://doi.org/10.1073/pnas.1008699107). Proc Natl Acad Sci. 2010;107(25):11325-11330.
[Alami et al., TDP-43 in neuronal RNA transport (2014)](https://doi.org/10.1016/j.neuron.2014.07.041). Neuron. 2014;83(5):1175-1189.
[Wang et al., TDP-43 phosphorylation (2018)](https://doi.org/10.1038/s41467-018-04062-4). Nat Commun. 2018;9(1):2565.
[Ambadu-Nkoudjo et al., TDP-43 in protein homeostasis (2022)](https://doi.org/10.1038/s41582-022-00648-3). Nat Rev Neurol. 2022;18(8):467-479.
[Bolognesi et al., TDP-43 aggregation mechanisms (2019)](https://doi.org/10.1016/j.jmb.2019.06.016). J Mol Biol. 2019;431(13):2241-2259.
[Smethurst et al., TDP-43 in astrocytes (2020)](https://doi.org/10.1093/brain/awaa164). Brain. 2020;143(7):2145-2160.
[泛 et al., TDP-43 interactome (2019)](https://doi.org/10.1038/s41467-019-11401-6). Nat Commun. 2019;10:3470.
[Konishi et al., TDP-43 and epigenetics (2022)](https://doi.org/10.1093/braincomms/fcac117). Brain Commun. 2022;4(3):fcac117.
[Ravits & La Spada, Motor neuron vulnerability (2009)](https://pubmed.ncbi.nlm.nih.gov/19562813/). Neurology. 2009;73(10):805-811.
[Brettschneider et al., TDP-43 staging in ALS (2013)](https://pubmed.ncbi.nlm.nih.gov/23440794/). Acta Neuropathol. 2013;125(4):511-523.References
Ou SH, Wu F, Harrisson D, et al, Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs (1995)
Buratti E, Baralle M, Molecular insights into TDP-43 and the ALS/FTD link (2010)
Neumann M, Sampathu DM, Kwong LK, et al, Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis (2006)
Unknown, Johnson JW, Dickensheets M, TDP-43 in neurodegenerative disease: A review (2024)
Lukavsky PJ, Daujotyte D, Tollervey JR, et al, Molecular basis of UG-rich RNA recognition by the human splicing factor TDP-43 (2013)
Chang CK, Wu TH, Wu CY, et al, The N-terminal dimerization is required for TDP-43 splicing activity (2019)
Buratti E, Brindisi A, Giombetti M, et al, TDP-43 binds heterogeneous nuclear ribonucleoprotein A2/B1 through the same interaction as the hnRNP A2 response element (2001)
Liu-Yesucevitz L, Bilgutay A, Zhang YJ, et al, Tar DNA binding protein-43 is sequestered in stress granules (2010)
Taylor JP, Brown RH, Cleveland DW, Decoding ALS: from genes to mechanism (2016)
Rascovsky M, Hodges JR, Knopman D, et al, Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia (2011)
Nelson PT, Dickson DW, Trojanowski JQ, et al, Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group recommendations (2019)
Lee EB, Lee VM, Trojanowski JQ, Gains or losses: Molecular mechanisms of TDP43-mediated neurodegeneration (2012)
Porta S, Xu Y, Teyssier N, et al, Distinct TDP-43 strains in neurodegenerative disease (2022)
Joyce PI, Fisher A, Fratta P, Animal models of ALS: recent progress and future directions (2023)
Polymenidou M, Lagier-Tourenne C, Hutt KR, et al, Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43 (2011)From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
- [Heat Shock Protein 70 Disaggregase Amplification](/hypothesis/h-5dbfd3aa) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: HSPA1A
- [PARP1 Inhibition Therapy](/hypothesis/h-69919c49) — <span style="color:#81c784;font-weight:600">0.67</span> · Target: PARP1
- [Arginine Methylation Enhancement Therapy](/hypothesis/h-19003961) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: PRMT1
- [RNA Granule Nucleation Site Modulation](/hypothesis/h-fffd1a74) — <span style="color:#81c784;font-weight:600">0.64</span> · Target: G3BP1
- [Glycine-Rich Domain Competitive Inhibition](/hypothesis/h-7e846ceb) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: TARDBP
- [Serine/Arginine-Rich Protein Kinase Modulation](/hypothesis/h-dca3e907) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: SRPK1
- [Low Complexity Domain Cross-Linking Inhibition](/hypothesis/h-69d383ea) — <span style="color:#ffd54f;font-weight:600">0.56</span> · Target: TGM2
Related Analyses:
- [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
Pathway Diagram
The following diagram shows the key molecular relationships involving Update TDP-43 protein page with comprehensive content discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)